Heartbeam, Inc. (BEATW) Stock Price & Analysis
Heartbeam, Inc. (BEATW) fell 11.56% to USD 0.05 as of June 10, 2026 at 17:50 UTC, according to Nexqual real-time market data.
BEATW last closed at USD 0.06; the session ranged USD 0.05–0.05 on volume of 2,600 shares. Market capitalization is —, with a 52-week range of USD 0.05–0.05 (NCM). Source: Nexqual, June 10, 2026 at 17:50 UTC.
Key Statistics (as of June 10, 2026 at 17:50 UTC)
| Price | USD 0.05 |
|---|---|
| Change | ▼ 11.56% (down) |
| Previous Close | USD 0.06 |
| Open | USD 0.29 |
| Day Range | USD 0.05 – 0.05 |
| 52-Week Range | USD 0.05 – 0.05 |
| Volume | 2,600 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (BEATW)
Nexqual's technical model rates BEATW "SELL" based on 3 bullish and 5 bearish signals across 67 daily candles, as of June 10, 2026 at 17:50 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 0 (oversold) |
| vs SMA50 | Below (USD 0.13) |
| MACD | -0.01 (negative) |
Analyst Ratings (BEATW)
Wall Street analysts rate BEATW "None", per Nexqual as of June 10, 2026 at 17:50 UTC.
| Consensus Rating | None |
|---|
Earnings (BEATW)
| Revenue Estimate | $106,670 |
|---|
Source: Nexqual, June 10, 2026 at 17:50 UTC.
Financial Health Score (BEATW)
Nexqual rates Heartbeam, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 17:50 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Major Backers & Investors (BEATW)
Notable institutional backers of Heartbeam, Inc. include Armistice Capital, LLC, Clear Street Group Inc., D'Orazio & Associates, Inc., according to Nexqual as of June 10, 2026 at 17:50 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 18.18% |
| Clear Street Group Inc. | 0.6% |
| D'Orazio & Associates, Inc. | 0.58% |
| Two Sigma Securities, LLC | 0.43% |
| Wells Fargo & Company | 0.27% |
Source: Nexqual, June 10, 2026 at 17:50 UTC.
From Heartbeam, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Our ability to develop higher resolution Electrocardiogram ("ECG") solutions is achieved through the development of our proprietary and patented technology platform that allows us to collect the heart's electrical activity from three dimensions and synthesize a 12-Lead ("12L") ECG from these signals.
- As a high-fidelity ECG system, it captures heart signals from three distinct directions for actionable heart health information and allows physicians to diagnose a wide range of non-urgent complex arrhythmias.   HeartBeam device in ready position (left) and the front view(right)   Our patented technology, along with a proprietary algorithm, allows us to generate signals similar to a 12L ECG without the need for cables, unlike a standard 12L ECG machine.
- The VALID-ECG pivotal study was a multicenter trial that enrolled 198 patients across five clinical sites in the US, including Allegheny Health Network, Atlanta Heart Specialists, Mount Sinai Hospital, Northwell Health and Piedmont Heart Institute.
- For some aspects of our proprietary technology, we rely on trade secret protection, while for others we pursue patent protection.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BFRIW | Biofrontera Inc. Warrants | USD 0.03 | ▼ 51.75% |
| ACONW | Aclarion, Inc. | USD 0.03 | ▼ 15.36% |
| BBLGW | BONE BIOLOGICS CORP C/WTS (TO P | USD 14 | ▲ 0% |
| AREBW | American Rebel Holdings, Inc. | USD 0 | ▼ 81.82% |
| DRMAW | Dermata Therapeutics, Inc. Warrant | USD 0.01 | ▼ 19.67% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 17:50 UTC. This page is informational and not investment advice.